We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesT2 Biosystems Inc

T2 Biosystems Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.009 USD -0.00 ( 10.00%)
Last update at 2026-11-11T21:00:00Z
VOLUME
35
Market Cap
84.48M
P/E
0.04

Momentum Score

…

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
2.60
Low
70.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

T2 Biosystems develops rapid infectious-disease diagnostics using a proprietary T2 magnetic resonance platform that detects pathogens directly from whole blood without culture. Long-term growth drivers include wider hospital adoption of rapid sepsis testing, new product approvals, and recurring consumable sales that could support revenue. The company may benefit from healthcare demand for faster diagnostics and potential cost-savings in inpatient care.

Key risks include limited commercial traction, ongoing losses and potential financing needs, regulatory and reimbursement hurdles, and competition from established diagnostics companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
7.18M
Revenue Per Share
1.86
Gross Profit TTM
-24.77M
Debt / Equity
-1.77
ROE
-622.14%
Net Debt
33.81M
ROCE
259.94%
Diluted EPS TTM
109.92

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -62.32M -49.24M -46.80M -59.01M -51.15M
Net income -63.37M -53.49M -49.21M -63.11M -51.15M
Selling general administrative 30.62M 28.53M 21.29M 27.30M 25.70M
Gross profit 1.17M 7.36M -3.15M -8.43M -4.90M
Reconciled depreciation 2.27M 2.54M 3.16M 3.64M 2.45M
Ebit -55.51M -42.97M -41.36M -52.06M -46.92M
Ebitda -55.47M -42.66M -41.29M -51.66M -44.47M
Depreciation and amortization 0.04M 0.32M 0.06M 0.40M 2.45M
Non operating income net other - - 0.09M 0.40M 0.62M
Operating income -55.51M -42.97M -41.36M -52.06M -45.09M
Other operating expenses 77.81M 71.03M 59.49M 60.39M 55.59M
Interest expense 6.08M 6.59M 5.50M 7.35M 6.68M
Interest income 0.01M 0.11M 0.01M 7.35M 6.68M
Net interest income -6.08M -6.47M -5.50M -7.35M -6.68M
Income tax expense 1.05M 4.25M 2.41M 4.11M 0.62M
Total revenue 22.30M 28.06M 18.13M 8.34M 10.50M
Total operating expenses 56.68M 50.33M 38.21M 43.63M 40.19M
Cost of revenue 21.14M 20.70M 21.28M 16.76M 15.40M
Total other income expense net -6.81M -6.27M -5.44M -6.95M 0.62M
Net income from continuing ops -62.00M -49.24M -46.80M -59.01M -51.15M
Net income applicable to common shares -62.65M -49.24M -46.80M -59.01M -51.15M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 34.80M 34.39M 60.54M 79.08M 28.49M
Other current assets 3.16M 2.58M 3.11M 2.66M 1.44M
Total liab 62.83M 74.36M 73.44M 70.35M 62.49M
Total stockholder equity -28.04M -39.97M -12.90M 8.73M -34.01M
Deferred long term liab - - - 0.10M -
Other current liab 11.50M 7.69M 7.16M 6.36M 13.63M
Common stock 0.00M 0.01M 0.17M 0.15M 0.05M
Capital stock 0.00M 0.01M 0.17M 0.15M 0.05M
Retained earnings -584.30M -534.53M -472.22M -422.98M -376.18M
Other liab - 4.90M 4.61M 4.78M 0.05M
Other assets 0.00M 1.69M 1.70M 0.69M 0.39M
Cash 15.69M 10.33M 22.25M 16.79M 11.03M
Total current liabilities 56.15M 10.51M 11.69M 9.80M 60.57M
Current deferred revenue 0.22M 0.17M 0.52M 0.23M 0.28M
Net debt 33.81M 48.89M 34.90M 38.98M 33.74M
Short term debt 42.90M 1.35M 1.17M 1.15M 42.90M
Short long term debt 41.28M - - - 42.90M
Short long term debt total 49.50M 59.22M 57.15M 55.77M 44.77M
Other stockholder equity 556.26M 494.56M 459.15M 431.55M 342.12M
Property plant equipment - 13.27M 14.44M 14.80M 5.84M
Total current assets 25.09M 19.42M 44.39M 53.58M 18.89M
Long term investments - - 0.00M 10.00M -
Net tangible assets - -39.97M -12.90M 8.73M -32.09M
Short term investments - 0.00M 10.00M 25.40M -
Net receivables 1.42M 2.16M 5.13M 5.10M 2.83M
Long term debt - 49.65M 47.79M 45.23M -
Inventory 4.82M 4.35M 3.91M 3.64M 3.60M
Accounts payable 1.53M 1.30M 2.83M 2.06M 3.75M
Accumulated other comprehensive income 0.00M - -0.00M 0.01M -13.24M
Common stock total equity - - - 0.15M 0.05M
Retained earnings total equity - - - -422.98M -376.18M
Non currrent assets other 0.00M 1.69M 1.70M 0.69M 0.39M
Non current assets total 9.71M 14.97M 16.14M 25.49M 9.59M
Capital lease obligations 8.21M 9.57M 9.36M 10.53M 3.86M
Long term debt total - - - 45.23M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 9.66M 25.25M -35.46M -0.76M -0.59M
Change to liabilities 0.00M 0.65M -1.33M 6.67M -0.16M
Total cashflows from investing activities - 24.79M -36.26M -0.76M -0.59M
Net borrowings - - - -0.88M -1.55M
Total cash from financing activities 29.05M 20.54M 85.61M 6.35M 49.66M
Change to operating activities - -0.85M -3.38M 1.35M -0.85M
Net income -62.00M -49.24M -46.80M -59.01M -51.15M
Change in cash -11.92M 6.45M 6.13M -39.77M 8.93M
Begin period cash flow 23.80M 17.34M 11.21M 50.98M 42.06M
End period cash flow 11.88M 23.80M 17.34M 11.21M 50.98M
Total cash from operating activities -50.63M -38.87M -43.22M -45.36M -40.14M
Issuance of capital stock 29.46M 19.97M 85.31M 6.65M 51.20M
Depreciation 2.27M 2.54M 3.16M 3.64M 2.45M
Other cashflows from investing activities - - 0.00M - -
Change to inventory -0.95M -1.94M 0.44M -0.91M -1.09M
Change to account receivables 2.97M -0.04M -2.27M -1.04M -1.32M
Sale purchase of stock -0.33M - - 0.58M 1.97M
Other cashflows from financing activities 0.22M 0.57M 0.30M 0.58M -0.59M
Change to netincome - 10.00M 6.96M 8.14M 12.51M
Capital expenditures 0.34M 0.46M 0.80M 0.76M 0.59M
Change receivables - - -2.27M -1.04M -1.32M
Cash flows other operating - - -1.52M -1.41M -1.38M
Cash and cash equivalents changes - - 6.13M -39.77M 8.93M
Change in working capital -0.50M -2.17M -6.54M 1.86M -3.94M
Stock based compensation 6.49M 7.09M 3.91M 5.46M 9.90M
Other non cash items 3.11M 3.93M 3.31M 2.41M 2.00M
Free cash flow -50.97M -39.33M -44.02M -46.12M -40.73M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TTOO
T2 Biosystems Inc		 -0.00
10.00%		 0.01 0.04 - 2.41 14.50 7.13 -1.17
TMO
Thermo Fisher Scientific Inc		 -15.12
2.11%		 702.59 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -1.34
0.57%		 233.97 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 24.91 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.17
0.68%		 24.93 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

T2 Biosystems Inc

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

101 Hartwell Avenue, Lexington, MA, United States, 02421

781 761 4646

https://www.t2biosystems.com

113

Name Title Year Born
Mr. John J. Sperzel III, B.Sc. Pres, CEO & Chairman 1963
Mr. Michael Terrence Gibbs Esq. Sr. VP & Gen. Counsel 1971
Mr. Alec J. Barclay Sr. VP 1980
Mr. John M. Sprague CPA Chief Financial Officer 1958
Ms. Kelley J. Morgan Chief People Officer 1976
Dr. Aparna Jha Ahuja M.D. Chief Medical Officer & Chairman of Scientific Advisory Board 1967
Mr. Brett A. Giffin Chief Commercial Officer 1959
Dr. Roger Smith Ph.D. Sr. VP of Science R&D 1965
Mr. John J. Sperzel III, B.Sc. President, CEO & Chairman 1963
Mr. Michael Terrence Gibbs Esq. Senior VP, General Counsel & Company Secretary 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…